Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov 16;44(Suppl 2):125.
doi: 10.1186/s13052-018-0559-9.

Ocular features in mucopolysaccharidosis: diagnosis and treatment

Alessandra Del Longo  1 , Elena Piozzi  2 , Fiammetta Schweizer  3
Affiliations
Review

Ocular features in mucopolysaccharidosis: diagnosis and treatment

Alessandra Del Longo et al. Ital J Pediatr. .

Abstract

Mucopolysaccharidoses (MPS) are a group of rare lysosomal storage disorders characterized by the accumulation of glycosaminoglycans (GAGs) in different parts of the eye. Ocular problems are very common in MPS children, and the cornea, sclera, trabecular meshwork, retina, and optic nerve may all be involved. Early diagnosis is very important to preserve the visual function, and the diagnosis requires experience and different evaluations. Follow-up is mandatory to allow a correct pathway to consequent therapy. This article aims to provide a review of ocular alterations and treatment options in MPS. The ophthalmologist is sometimes the first physician who can suspect a metabolic disease and can help to make the correct diagnosis. It is important to stimulate awareness of MPS among ophthalmologists.

Keywords: Corneal clouding; Diagnosis MPS; Eye manifestations; MPS; Mucopolysaccharidosis; Treatment MPS.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

The parents of the female patient reported in the case report signed an agreement for anonymized publication of the clinical data.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Classification of corneal clouding
Fig. 2
Fig. 2
Corneal ocular coherence tomography (OCT). a Transparent cornea. b Corneal clouding in mucopolysaccharidosis (MPS) type I
Fig. 3
Fig. 3
An 11-year-old MPS VI patient who underwent left corneal transplant. A transparent cornea with no inflammation in the left eye, and corneal clouding in the non-transplanted right eye
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kottler Ulrike, Demir Deniz, Schmidtmann Irene, Beck Michael, Pitz Susanne. Central Corneal Thickness in Mucopolysaccharidosis II and VI. Cornea. 2010;29(3):260–262. doi: 10.1097/ICO.0b013e3181b55cc1. - DOI - PubMed
    1. Fahnehjelm KT, Ashworth JL, Pitz S, Olsson M, Törnquist AL, Lindahl P, et al. Clinical guidelines for diagnosing and managing ocular manifestations in children with mucopolysaccharidoses. Review article. Acta Ophthalmol. 2012;90:595–602. doi: 10.1111/j.1755-3768.2011.02280.x. - DOI - PubMed
    1. Ashworth JL, Biswas S, Wraith E, Loyd IC. The ocular features of the mucopolysaccharidoses. Eye. 2006;20:553–563. doi: 10.1038/sj.eye.6701921. - DOI - PubMed
    1. Ashworth JL, Kruse FE, Bachmann B, Tormene AP, Suppiej A, Parini R, Guffon N. Ocular manifestation in the mucopolysaccharidoses—review. Clin Exp Ophthalmol. 2010;28:12–22. doi: 10.1111/j.1442-9071.2010.02364.x. - DOI
    1. ALROY JOSEPH, HASKINS MARK, BIRK DAVID E. Altered Corneal Stromal Matrix Organization is Associated with Mucopolysaccharidosis I, III and VI. Experimental Eye Research. 1999;68(5):523–530. doi: 10.1006/exer.1998.0622. - DOI - PubMed

MeSH terms